CompletedPhase 3

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

480 participants

Plain-language summary

To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Outpatients * Sexually active women participating in the study must use a medically acceptable form of contraception * Subjects must have a primary diagnosis of major depressive disorder Exclusion Criteria: * Treatment with DVS-233 SR at any time in the past * Treatment with venlafaxine (immediate release \[IR\] or extended release \[ER\]) within 90 days of study day 1 * Known hypersensitivity to venlafaxine (IR or ER)

Trial details

NCT IDNCT00072774

SponsorWyeth is now a wholly owned subsidiary of Pfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2004-11

View on ClinicalTrials.gov More Major Depressive Disorder trials